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ABSTRACT The GM2 activator deficiency (also known as
the AB variant), Tay–Sachs disease, and Sandhoff disease are the
major forms of the GM2 gangliosidoses, disorders caused by
defective degradation of GM2 ganglioside. Tay–Sachs and Sand-
hoff diseases are caused by mutations in the genes (HEXA and
HEXB) encoding the subunits of b-hexosaminidase A. The GM2
activator deficiency is caused by mutations in the GM2A gene
encoding the GM2 activator protein. For degradation of GM2
ganglioside by b-hexosamindase A, the GM2 activator protein
must participate by forming a soluble complex with the gangli-
oside. In each of the disorders, GM2 ganglioside and related lipids
accumulate to pathologic levels in neuronal lysosomes, resulting
in clinically similar disorders with an onset in the first year of life,
progressive neurodegeneration, and death by early childhood.
We previously have described mouse models of Tay–Sachs (Hexa
2y2) and Sandhoff (Hexb 2y2) diseases with vastly different
clinical phenotypes. The Hexa 2y2 mice were asymptomatic
whereas the Hexb 2y2 mice were severely affected. Through gene
disruption in embryonic stem cells we now have established a
mouse model of the GM2 activator deficiency that manifests an
intermediate phenotype. The Gm2a 2y2 mice demonstrated
neuronal storage but only in restricted regions of the brain
(piriform, entorhinal cortex, amygdala, and hypothalamic nu-
clei) reminiscent of the asymptomatic Tay–Sachs model mice.
However, unlike the Tay–Sachs mice, the Gm2a 2y2 mice
displayed significant storage in the cerebellum and defects in
balance and coordination. The abnormal ganglioside storage in
the Gm2a 2y2 mice consisted of GM2 with a low amount of GA2.
The results demonstrate that the activator protein is required for
GM2 degradation and also may indicate a role for the GM2
activator in GA2 degradation.
The GM2 gangliosidoses are severe neurodegenerative disor-
ders caused by excessive accumulation of GM2 ganglioside.
Three genetic forms exist: Tay–Sachs disease, Sandhoff dis-
ease, and the GM2 activator deficiency (also known as the AB
variant) (reviewed in ref. 1). Tay–Sachs disease is caused by
mutations in the HEXA gene, Sandhoff disease by mutations
in the HEXB gene, and the GM2 activator deficiency by
mutations in the GM2A gene. The HEXA and HEXB genes
encode the a- and b-subunits, respectively, of the lysosomal
enzyme, b-hexosaminidase. The subunits dimerize to form the
three b-hexosaminidase isozymes, A (ab), B(bb), and S (aa).
The GM2A gene encodes the GM2 activator protein. In each
disorder, the respective genetic lesion results in impairment of
the degradation of GM2 ganglioside and related substrates.
In humans, in vivo GM2 ganglioside degradation requires the
GM2 activator protein to form a complex with GM2 ganglioside.
b-Hexosaminidase A then is able to interact with the activator-
ganglioside complex and remove the terminal N-acetylgalac-
tosamine residue from the oligosaccharide portion of the gangli-
oside. In both Tay–Sachs and Sandhoff diseases, ganglioside
degradation is impaired due to an absence of b-hexosaminidase
A. The homodimeric b-hexosaminidase isozymes, S and B,
cannot effectively substitute for b-hexosaminidase A in ganglio-
side degradation. It is believed that the function of the activator
protein is to transform the hydrophobic, membrane-bound gan-
glioside into a substrate complex that is accessible to the water-
soluble enzyme (2). Therefore, in the GM2 activator deficiency,
the ganglioside is refractory to enzymatic hydrolysis by b-hex-
osaminidase A. In each disease, a massive accumulation of GM2
ganglioside and related lipids occurs in neuronal lysosomes,
resulting in severe cellular malfunction and damage. The clinical
phenotype of each disease is nearly identical. In the most severe
forms, the onset of the disease occurs during the first year of life.
Rapidly progressing neurodegeneration culminates in demise
usually by the age of 4. Disorders of lesser severity and later-onset
result when mutations lead to a partial deficiency in ganglioside
degradation capacity.
Through targeted gene disruption of the Hexa and Hexb
genes in mouse embryonic stem (ES) cells, we previously have
described the creation of mouse models corresponding to
Tay–Sachs and Sandhoff diseases (3–5). Unlike the human
diseases, the two mouse models were of dramatically different
phenotypes as a result of differences in the ganglioside deg-
radation pathway between mice and humans. The Tay–Sachs
model developed ganglioside accumulation in restricted re-
gions of the brain but was asymptomatic. The Sandhoff disease
model exhibited much more extensive ganglioside accumula-
tion and developed a severe neurologic phenotype.
We now have established mice with a disrupted Gm2a gene as
a model for the third form of the GM2 gangliosidoses. Similar to
the Hexa 2y2 mice, the Gm2a 2y2 mice demonstrated storage
in restricted regions of the brain. However, these mice also
displayed some significant differences. They exhibited storage in
the cerebellum, a site of minimal pathology in the Hexa 2y2 mice
(4) and developed defects in balance and motor coordination.
This mouse model of the GM2 activator deficiency is, thus, of an
intermediate phenotype when compared with the severely af-
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fected Sandhoff model and the asymptomatic Tay–Sachs model.
The basis for the distinct phenotypes of the human and mouse
GM2 gangliosidoses are species-specific differences in the gangli-
oside degradation pathway.
MATERIALS AND METHODS
Targeting Vector Construction. We previously have con-
structed a plasmid containing both the neomycin-resistance
(neo) gene and the thymidine kinase gene in the pBluescript
KS vector (3). Genomic clones from a 129ySV strain library
(Stratagene; catalogue no. 946306) containing the mouse
Gm2a gene were isolated and characterized. A 4.5-kb genomic
fragment containing part of intron 2 was inserted between the
SalI and NotI sites downstream of the Neo gene. Next, a 4.5-kb
genomic fragment containing part of the exon 4 and down-
stream region was cloned into the XhoI site between the
thymidine kinase and Neo genes. The organization of the
targeting vector is illustrated in Fig. 1A. The design of the
targeting vector would result in a 1-kb deletion that includes
the entire exon 3, entire intron 3, and part of exon 4.
Selection of Targeted ES Cells and Generation of Mutant
Mice. The targeting vector (50 mg) was linearized with SspI
endonuclease and introduced into the J1 line (6) of ES cells (1.6 3
107 cells) by electroporation (400 V and 25 mF) in a Bio-Rad
Gene Pulser. Targeted clones were isolated as described (3).
Targeted ES cells lines Act-4 and Act-25 were injected into the
blastocysts of 3.5-day C57BLy6 embryos. Highly chimeric male
mice were obtained and bred to C57BLy6 females. The agouti
offspring were tested for transmission of the disrupted allele by
Southern blot analysis. Heterozygous matings were set up to
generate homozygous mutant mice.
Biochemical Analysis. b-Hexosaminidase assays were per-
formed as described (3). Methodology for the analysis of brain
lipids from gray and white matter has been described (5).
Pathology. Six Gm2a 2y2 and two Gm2a 1y2 mice, ages
ranging from 2 to 7 months, were studied. Mice were anesthetized
and perfused with phosphate-buffered 4% paraformaldehyde
(pH 7.4). The brain, spinal cord, and pieces of visceral organs
from two of the Gm2a 2y2 mice were processed for paraffin
sections, cut and stained with hematoxylin-eosin, solochrome-
eosin, Luxol-fast blue-periodic acid-Schiff, and Bielschowsky
stains. In other mice the cerebrum, cerebellum, brainstem, and
spinal cord were cryoprotected by immersion in 0.1 M phosphate
buffer (pH 7.4) containing 30% sucrose, snap-frozen in a Hist
Bath (Shandon, Pittsburgh), and serially sectioned at 7 mm thick
with a Frigocut 2800 (Leica, Germany). Every fourth section was
stained with periodic acid-Schiff and counter-stained lightly with
hematoxylin.
Behavioral Methods. Subjects were 24 mice (six wild type, six
Gm2a 1y2, and 12 Gm2a 2y2). All procedures were approved
by the National Institute of Mental Health Animal Care and Use
Committee and followed the National Institutes of Health guide-
lines, ‘‘Using Animals in Intramural Research.’’ Mice were 13
weeks old at the start of testing. Body weights were measured
biweekly during the 20-week testing period. There were no
significant differences in body weight across treatment groups.
Male mice weighed significantly more than females across all
groups (F1,18 5 32.59, P , 0.0001). Repeated-measures analysis
showed that there was a significant increase in weight over the
20-week testing period across all groups combined (F9,162 5 83.61,
P , 0.0001), but no difference in weight gain among groups.
Rotorod. The ability to maintain balance on a rotating cylinder
was measured with a standard rotorod apparatus (model 7650,
Ugo Basile, Varese, Italy). The cylinder was 3.2 cm in diameter
and covered with textured rubber. Mice were confined to a
section of the cylinder 6.0 cm long by gray Plexiglas dividers. Each
mouse was placed on the cylinder, which increased rotation speed
over a 5-min period from 5 to 40 revolutions per min. Rotational
speed at which the mouse fell off the rotating cylinder was
measured. Mice that fell in less than 15 s were given a second trial.
Mice that did not fall during the 300-s trial period were removed
and given a score of 40 rpm. Rotorod testing was conducted once
every 2 weeks for 20 weeks.
Open field behavior. Exploratory locomotor activity was
measured in an open field as described (3, 5). Locomotor
activity was measured once every 2 weeks for 20 weeks.
Passive avoidance. Passive avoidance learning was tested in
a mouse shuttle box as described (3, 5).
Shock threshold. Testing was performed as described (7).
Tail-flick nociception. Each mouse was placed within a restrain-
ing tube on a tail-flick monitor (Omnitech Electronics, Colum-
bus, Ohio). The mouse’s tail protruded from a hole in the
restraining tube and was allowed to move freely. The mouse’s tail
was placed in a tail guide, which contained a photobeam for
precise measurement of tail-flick latencies. A coil, offset in the
floor of the monitor, was used to apply a heat stimulus to the
mouse’s tail. The temperature of the heating coil rose 15.0°C from
room temperature in 15 s. The time it took for the mouse to flick
its tail away from the heat was measured automatically by
completing the photobeam upon tail flick.
Hot-plate nociception. Each mouse was placed on a hot plate
maintained at 55°C (Nuova II; Thermolyne, Dubuque, Iowa).
A plastic cylinder 15 cm in diameter and 12.5 cm high confined
the mouse to the surface of the hot plate. The time it took the
mouse to jump or lick its paw was measured with a stop watch.
Mice were then immediately removed from the hot plate. Mice
that did not jump or lick a paw within 10 s were removed from
the hot plate and given a score of 10 s.
FIG. 1. Targeted disruption of the Gm2a locus. (A) The mouse
Gm2a locus is indicated on top, the structure of the mouse Gm2a
targeting vector is in the middle, and the predicted structure of the
homologously recombined locus is on the bottom. R, EcoRI site; TK,
thymidine kinase gene, E, exon. (B) Southern analysis of ES clone and
mouse tail DNA. Genomic DNA was isolated, digested with EcoRI
endonuclease, electrophoresed on a 1% agarose gel, and transferred
to GeneScreenPlus membranes. The hybridization probe is shown in
A. (Left) Lane 1 shows a G418-resistant clone that had not undergone
homologous recombination. Lanes 2 and 3 show correctly targeted
clones. (Right) Tail DNA from Gm2a 2y2, 1y1, and 1y2 mice. (C)
Northern analysis of testis and kidney from Gm2a 1y1 and 2y2 mice.
Twenty micrograms of total RNA from testis or kidney RNA was
subjected to electrophoresis through a 1.2% formaldehydeyagarose
gel, transferred to GeneScreenPlus membrane, and hybridized with
Gm2a cDNA probe. Lanes 1 and 3, testis; lanes 2 and 4, kidney.
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Startle responseyprepulse inhibition. Startle response and pre-
pulse inhibition were measured using two SR-Lab startle cham-
bers (San Diego Instruments, San Diego, CA). Each chamber
contained a Plexiglas cylinder 5.1 cm in diameter, resting on a
Plexiglas frame (20.4 cm length 3 12.7 cm width 3 0.4 cm thick)
within a ventilated enclosure. The startle session was immediately
preceded by a 5-min acclimation period in the startle chambers.
The mice were then tested with a series of white noise bursts in
the chamber, presented through a loudspeaker mounted 28 cm
above the animal. Each startle session consisted of 42 trials over
a 10.5-min period. There were seven trial types: six trials on which
no stimulus was presented, six trials on which only the startle
stimulus was presented, and 30 trials on which the startle stimulus
was preceded by one of five ‘‘prepulse’’ stimuli, by 100 ms. The
startle stimulus was a 40-ms, 120-dB burst of white noise. The
prepulse stimuli were 20-ms bursts of 74, 78, 82, 86, or 90-dB white
noise, each presented on six trials. The trials on which no stimulus
was presented were used to measure baseline movement in the
cylinders. The seven trial types were presented in pseudorandom
order such that each trial type was presented once within a block
of seven trials. The intertrial interval ranged from 10–20 s with an
average of 15 s. The startle response was recorded for 65 ms
(sampling the response once every 1 ms), starting with the onset
of the startle stimulus. The maximal startle amplitude recorded
during the 65-ms sampling window was used as the dependent
variable.
Statistical analysis. Because there were no differences on any
measure between wild types and heterozygotes, these two
groups were combined into a single control group for statistical
analysis. Two-group comparisons were made using unpaired
Student’s t tests. Analyses of performance over time were
made using two-factor repeated-measures ANOVA.
RESULTS
Targeted Disruption of the Mouse Gm2a Gene. Using a
mouse Gm2a cDNA (8) as probe, we isolated genomic DNA
fragments covering the entire mouse Gm2a gene from a 129ysv
strain library. Like the human GM2A gene (9), the mouse
Gm2a gene has four exons (Fig. 1A). The exon-intron borders
are completely conserved between human and mouse (Y.L.
and R.L.P., unpublished results).
To disrupt the Gm2a gene in mouse ES cells, a replacement-
type of targeting vector was created with these genomic segments.
A 1-kb region covering exon 3 and the entire coding region of
exon 4 was deleted and replaced with the MC1NeopolyA cassette.
The targeting vector had a total of 9 kb of homologous genomic
sequence with 4.5 kb of sequence flanking each side of the Neo
cassette. Additionally, the thymidine kinase gene was positioned
outside the homologous sequences to enable selection against
nonhomologous integrants.
The targeting vector was linearized and electroporated into
the J1 ES cell line. The ganciclovir counter selection resulted
in a 7-fold enrichment of homologous recombinants. Genomic
DNA from G418- and ganciclovir-resistant clones was ana-
lyzed by Southern analysis. Of the 113 colonies examined,
DNA from 13 contained the 6.5-kb EcoRI band diagnostic of
a homologous recombination event (Fig. 1B). Cells from two
of the targeted ES clones were injected into C57BLy6 mouse
blastocysts, and one of the clones produced highly chimeric
male mice that transmitted the targeted allele through the
germ line. The heterozygotes were intercrossed to obtain mice
homozygous for the disrupted gene (Fig. 1B).
The Gm2a Homozygous Mutant Mouse Has a Total GM2
Activator Deficiency with Normal Hexosaminidase Activity. The
targeting event resulted in a deletion of the C-terminal 112 amino
acids of the 162 total amino acids contained within the mature
GM2 activator protein. The deletion was evidenced by genomic
Southern blot analysis using a cDNA probe composed of the
coding sequence presumed removed during homologous recom-
bination. With this probe, no hybridization signal was detected
from the homozygous mutant mice (data not shown). The total
RNA of testis and kidney from wild-type and Gm2a 2y2 mice
was examined by Northern blot analysis (Fig. 1C). A '2.3-kb
mRNA was detected in wild-type mice tissues. No Gm2a-related
transcript was present in the Gm2a 2y2 mice tissues, demon-
strating that the targeting event resulted in a null allele.
Like humans with GM2 activator deficiency, the Gm2a 2y2
mice had normal levels of b-hexosaminidase activity. Liver
extracts from wild-type, Hexa 2y2, Hexb 2y2, and Gm2a
2y2 were chromatographed on a Mono Q column under
conditions that separate b-hexosaminidase A and B (3). Dif-
ferent from the Hexa 2y2 and Hexb 2y2 mice that lacked one
or both of the two isozymes, the Gm2a 2y2 mice had normal
levels of b-hexosaminidase isozyme activity (data not shown)
Glycolipid Accumulation in Gm2a 2y2 Mice. Sphingolipids
were isolated from gray matter and white matter of brains from
wild-type, Hexa 2y2, Hexb 2y2, and Gm2a 2y2 mice at 4
months of age. The glycolipid fraction was then separated by
high-performance thin-layer chromatography, and the GM2
and GA2 species were quantified (Fig. 2). The Gm2a 2y2 mice
accumulated GM2 ganglioside in their brains at a level com-
parable to the Hexa 2y2 mice but less than the Hexb 2y2
mice. As previously described (5) the Hexb 2y2 mice also
accumulated a large amount of GA2. The Gm2a 2y2 mice did
not accumulate large amounts of GA2. However, a closely
migrating band made it difficult to determine if a small amount
of GA2 was present in the Gm2a 2y2 mice by this analysis.
FIG. 2. Glycolipid accumulation in the brains of 4-month-old Hexa
2y2, Hexb 2y2, and Gm2a 2y2 mice. (A) The sphingolipid fraction
of brain tissues was separated by thin-layer chromatography. GM2 and
GA2 standards are indicated. g, gray matter; w, white matter. (B) The
sphingolipid fraction of gray and white matter was quantified, respec-
tively (mmolyg wet weight).
8140 Medical Sciences: Liu et al. Proc. Natl. Acad. Sci. USA 94 (1997)
Therefore the gray and white matter glycolipids were sepa-
rated in a two-dimensional high-performance thin-layer chro-
matography system (first solvent: CHCl3yMeOHy7 M NH4OH
(65:25:4 volyvol), second solvent system: CHCl3yMeOHyH2O,
0.22% CaCl2 (60:35:8 volyvol). In this analysis, a heavy GA2
accumulation was found in Hexb 2y2 mice, no GA2 was
detected in Hexa 2y2 mice and, most importantly, a slight
accumulation was identified in the Gm2a 2y2 mice.
The ganglioside degradation pathway of the Gm2a 2y2 mice
was analyzed by administration of GM1 ganglioside radiolabled in
the ceramide moiety to cultured embryonic fibroblasts (Fig. 3).
As a result of the absence of both b-hexosaminidase A and B, the
fibroblasts from Hexb 2y2 and from double-knockout (Hexa
2y2 and Hexb 2y2) mice could only degrade GM1 to GM2 and
GA2 (5, 10). As described previously, Hexa 2y2 fibroblasts
bypassed this block as a result of sialidase action on GM2 to
produce GA2 and the subsequent degradation of GA2 by b-hex-
osaminidase B (5). Like the Hexa 2y2 fibroblasts, but distinct
from the Hexb 2y2 fibroblasts, the Gm2a 2y2 fibroblasts also
degraded GM1 to ceramide, demonstrating that the catabolic
pathway in these mice was not completely blocked. However, the
Gm2a 2y2 fibroblasts accumulated a higher quantity of GA2
than that found in the Hexa 2y2 fibroblasts.
Gm2a 2y2 Mice Show Restricted Neuronal Storage. Gm2a
2y2 mice aged 2 to 7 months were examined. Although the
central nervous system pathology progressively worsened with
age, the overall distribution of the pathology was the same
regardless of the age of the animal. Unless noted otherwise, the
description here is given for 5-month-old mice. Examination was
carried out using periodic acid-Schiff staining on frozen sections,
which results in the ganglioside storage appearing red. As previ-
ously described, the Hexa 2y2 mice showed a pattern of storage
restricted to certain regions of the brain whereas the Hexb 2y2
mice exhibited storage throughout the brain. In the cerebral
cortex, the pattern of neuronal storage in Gm2a 2y2 mice was
very similar to that of the Hexa 2y2 mice (4). The storage was
predominately in large pyramidal neurons in the middle layer
(Fig. 4 A and B). In contrast, almost all neurons in the cerebral
cortex from the Hexb 2y2 mice contained storage material (Fig.
4C). Also like the Hexa 2y2 mice (4), storage in the Gm2a 2y2
mice was most pronounced in certain areas such as in the
piriform, entorhinal cortex, and amygdala as well in the hypo-
thalamic nuclei (data not shown). In both the Gm2a 2y2 and
Hexa 2y2 mice little storage was observed in spinal cord and
visceral organs (refs. 4 and 5; data not shown).
The major difference between the neuropathology of the
Gm2a 2y2 and Hexa 2y2 mice was the presence of storage cells
in the cerebellum in the former. In Gm2a 2y2 mice, prominent
storage material was present in the glial cells in the molecular and
granular cell layers, and Purkinje and granular cell neurons (Fig.
4 D and E). A similar distribution of cerebellar storage also was
observed in the youngest Gm2a 2y2 mice examined (2 months
old). Very little storage was observed in comparable areas of the
Hexa 2y2 cerebellum at any age. In the Hexb 2y2 mice, storage
was abundant in the Purkinje cells as well as in the granular cells
and molecular layer of the cerebellum (Fig. 4F).
Gm2a 2y2 Mice Are Viable but Have Neurologic Distur-
bances. Heterozygous matings yield Gm2a 2y2 progeny in a
Mendelian fashion, indicating that there was no embryonic
lethality. Gm2a 2y2 mice grow normally and have survived for
more than 1 year. Both males and females are fertile. They can
be bred to each other and give litters of normal size.
The Gm2a 2y2 mice were tested to determine their neuro-
logic function. Motor coordination and balance was measured
with a standard rotorod apparatus. A total of 24 mice (six wild
type, six Gm2a 1y2, and 12 Gm2a 2y2) were tested beginning
at 13 and ending at 31 weeks of age. As shown in Fig. 5A, overall
rotorod performance was significantly impaired in the knockouts,
compared with the controls (F1,22 5 5.18, P 5 0.033). Analysis of
the groups individually demonstrated that the controls displayed
a significant improvement in rotorod performance over the
20-week testing period (F9,99 5 4.36, P , .0001), while the
performance of the knockouts remained stable (F9,99 5 0.89, P 5
0.534). Using open field testing, there was no significant differ-
ence between Gm2a 2y2 and controls in horizontal activity
(F1,22 5 3.99, P 5 0.058) or vertical activity (F1,22 5 0.215, P 5
0.647), indicating the poor performance of the Gm2a 2y2 mice
on the rotorod was not due to a generalized lack of mobility.
The passive-avoidance task was used as a test for learning and
memory. Fig. 5B illustrates passive-avoidance performance on
the training and testing days for Gm2a 2y2 and control mice.
There was no difference between groups on latency to enter the
dark chamber on the training trial (t20 5 0.20, P 5 0.657).
However, there was a small, but significant, difference in latency
to enter the dark chamber 24 hr after a foot shock in that location
(t20 5 2.42, P 5 0.025), indicating a possible memory deficit in
the Gm2a 2y2 mice. No significant differences were detected
among genotypes with the shock threshold test or with the
tail-flick and hot-plate tests for nociception, suggesting that the
deficit in passive-avoidance learning was not due to shock or pain
insensitivity. No significant differences were detected among
genotypes on prepulse inhibition, indicating that sensorimotor
gating was normal in the Gm2a 2y2 mice.
DISCUSSION
We have established mouse models for the three major forms
of the GM2 gangliosidoses: Tay–Sachs disease, Sandhoff dis-
ease, and, as described here, the GM2 activator deficiency (AB
variant). Although the three human disorders are very similar
in clinical phenotype, each of the mouse models displays a
distinct phenotype. The Sandhoff mice (Hexb 2y2), lacking
b-hexosaminidase A and B, are the most severely affected with
an early onset of severe, progressing motor dysfunction and a
shortened life span. In contrast, the Tay–Sachs mice (Hexa
FIG. 3. Ganglioside metabolism in gangliosidosis fibroblasts.
[3H]GM1 ganglioside was added to fibroblast cultures for 120 hr. The
glycolipids then were extracted, analyzed by thin-layer chromatography
and visualized on a RaytestyFuji BAS 1000 phosphoimager. (Left to right)
Hexb 2y2, Hexa 2y2, DKO (double knockout, both Hexa 2y2 and
Hexb 2y2), Gm2a 2y2, and control (wild-type) embryonic fibroblasts.
Cer, ceramide; FFA, free fatty acid; GlcCer, glucosylceramide; LacCer,
lactosylceramide.
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2y2), lacking b-hexosaminidase A, appear to be phenotypi-
cally normal. The Gm2a 2y2 mice, which do not express the
activator protein, are of an intermediate phenotype with motor
function abnormalities but with a normal life span.
The basis for the phenotypic differences between the human
and mouse gangliosidoses is in large measure the result of
different degradative pathways. Based on the biochemical differ-
ences between the Hexa 2y2 and Hexb 2y2 mice, we have
proposed two independent catabolic pathways for GM2 in mice
(5). In one, GM2 is degraded to GM3 primarily by b-hexosamini-
dase A with the GM2 activator protein. This is the major and
almost exclusive pathway in humans. In a second pathway specific
to the mouse, GM2 is degraded by sialidase first to GA2 and then
by b-hexosaminidase B or A to lactosylceramide (Fig. 6). Con-
sequently, the Hexa 2y2 mice lacking b-hexosaminidase A
accumulate GM2, but not GA2, and are asymptomatic. The Hexb
2y2 mice lacking both b-hexosamindase A and B accumulate
both GM2 and GA2 due to blocks in both pathways and show a
severe phenotype. In the brain of the Gm2a 2y2 mice there is
accumulation of GM2 with a small amount of GA2. The GM2
accumulation proves that the activator protein is essential for the
degradation of GM2 ganglioside via the formation of GM3 and
FIG. 4. Gm2a 2y2 and Hexa 2y2 mice show restricted storage in the brain compared with Hexb 2y2 mice. All panels are photomicrographs
of frozen sections stained by periodic acid-Schiff. B displays cerebral cortex from the Gm2a 2y2 mouse with storage predominant in large pyramidal
neurons in the middle layer (bracketed) similar to the Hexa 2y2 mouse in A; while nearly all neurons contain storage in the Hexb 2y2 mouse
(C). (330.) (E) The cerebellum of the Gm2a 2y2 mouse shows storage in some Purkinje cells (arrows), glial cells in the molecular cell layer, and
some granular cell neurons (may be also glial cells) in the granular cell layers. (D) In a similar section from a Hexa 2y2 mouse minimal storage
is seen in a few glial cells in the molecular layer but not in Purkinje cells (arrows). (F) The Hexb 2y2 mouse shows more storage in Purkinje cells
(arrows), granular cells, and molecular layer. (3300.)
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demonstrates, together with the results from the Hexa 2y2 mice,
that both the activator protein and b-hexosaminidase A are
needed for this reaction in mice as in humans (Fig. 6).
The low level of GA2 storage in the Gm2a 2y2 mice indicates
that the hexosaminidase-mediated degradation of GA2 can pro-
ceed in the absence of the activator protein. However, evidence
also suggests that the activator protein is likely required for this
reaction to proceed at an optimal rate. In the ganglioside feeding
experiment Gm2a 2y2 fibroblasts contained a higher quantity
GA2 than Hexa 2y2 or wild-type fibroblasts. This result is
consistent with the GM2 activator protein increasing the rate of
GA2 degradation by hexosaminidase A andyor B. Indeed, admin-
istration of recombinant human GM2 activator protein to mouse
Gm2a 2y2 fibroblasts enhances the degradation of radiolabled
GA2 (A.H. and K. Sandhoff, unpublished results).
The pathologic differences between the Hexa 2y2 and Gm2a
2y2 mice also indicate that ganglioside catabolism pathway is
not equivalent in the two types of mice. For the most part, the
regions of the brain affected by storage were very similar in the
two knockout mice indicative of a common degradative block at
GM2 to GM3 (Fig. 6). A major difference between the Gm2a 2y2
and the Hexa 2y2 mice was the presence of storage in the
cerebellar neurons and glial cells of the Gm2a 2y2 mice. The
impaired motor coordination detected in the Gm2a 2y2 mice
was consistent with significant storage in this portion of the brain.
With minimal storage in this cerebellar region, the Hexa 2y2
mice were asymptomatic throughout their normal life span.
Cerebellar storage in the Gm2a 2y2, but not the Hexa 2y2,
mice must be due to the inability of the activator-independent
degradative pathway to handle the level of ganglioside substrate
produced in this region of the brain. This accumulation in the
Gm2a 2y2 cerebellum could be explained by a lower rate of GA2
degradation in the absence of activator relative to when activator
is present in the Hexa 2y2 cerebellum. As illustrated by the
late-onset forms of the GM2 gangliosidoses, very low levels of
degrading activity can drastically alter the degree of ganglioside
storage (11, 12).
The three gangliosidosis mice provide models for the human
disorders, allowing evaluation of potential therapies including
protein and gene replacement, stem cell transplantation, and
substrate depravation strategies (13). In addition, the degradative
pathways in the mildly affected mice suggest possible therapies
through manipulation of the human degradative pathway.
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FIG. 5. Gm2a 2y2 mice show difference in motor coordination
and possible memory deficit when compared with control mice. (A)
The ability to maintain balance on a rotating rotorod was measured
every 2 weeks beginning at 13 weeks of age. Mean (6SEM) speed to
fall from the rotorod for Gm2a 2y2 (n 5 12) and controls (n 5 12).
Controls stayed on the rotorod significantly longer than Gm2a 2y2
mice overall. Controls exhibited improved rotorod performance over
the 20-week testing period, while performance of the Gm2a 2y2 mice
remained stable. (B) Mean (6SEM) latency to enter a dark chamber
on the passive avoidance task for Gm2a 2y2 (n 5 10) and controls
(n 5 12). Gm2a 2y2 mice were quicker to enter the dark chamber on
the test trial, indicating poorer retention for the aversive experience of
the previous day.
FIG. 6. The ganglioside degradation pathways in gangliosidosis
mice. The normal degradative pathway in mice has been described (5).
Also shown are proposed degradative pathways in Hexa 2y2, Hexb
2y2, and Gm2a 2y2 mice. This scheme does not take into account
the minor contribution of b-hexosaminidase S on GM2 hydrolysis. GM2,
GM2 ganglioside; GM3, GM3 ganglioside; GA2, GA2 glycolipid; LacCer,
lactosylceramide; HEXA, b-hexosaminidase A; HEXB, b-hexosamini-
dase B; GM2A, GM2 activator protein.
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